CLAIM CARD
Several clinically relevant endpoints are represented by only a single source, precluding internal replication within the corpus. The cardiometabolic outcome class—specifically GLUT4 translocation and insulin-sensitivity markers—is supported by one laboratory study (Kondo 2024) and one preclinical investigation (Molnar 2021), but no human trial has confirmed these glucose-uptake findings in vivo. Immune-inflammation endpoints are likewise touched by a single preclinical source (Rasooli 2019) examining sepsis-induced liver injury in rats, with no corroborating clinical data. Translational relevance to humans remains uncertain. When outcomes depend on lone studies, effect estimates cannot be triangulated and the risk of spurious or context-specific findings remains unquantifiable.
Evidence grade: exploratory
Contradiction status: none
Publication: d8263221-9f0a-41ec-95ec-4711d2e47db6
Provenance: Derivation Web chain
Citation Support
source_1Somlyai 2025source_2Somlyai 2023source_3Boros 2021source_4Korchinsky 2024source_5Molnar 2021